Profile data is unavailable for this security.
About the company
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.
- Revenue in GBP (TTM)2.35bn
- Net income in GBP267.61m
- Incorporated2005
- Employees9.31k
- LocationHikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
- Phone+44 207 399 2760
- Fax+44 207 399 2761
- Websitehttps://www.hikma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Tiantan Biological Products Corp | 635.79m | 153.21m | 4.05bn | 5.30k | 26.58 | 3.43 | -- | 6.37 | 0.7424 | 0.7424 | 3.09 | 5.76 | 0.395 | 0.8406 | 20.21 | 1,156,602.00 | 13.00 | 11.93 | 18.41 | 16.79 | 51.52 | 50.69 | 32.92 | 29.69 | 3.63 | -- | 0.0086 | 16.24 | 16.44 | 12.94 | 39.58 | 20.45 | 15.19 | 23.56 |
| Ono Pharmaceutical Co Ltd | 2.44bn | 251.01m | 4.06bn | 4.29k | 15.25 | 0.9753 | 10.51 | 1.66 | 106.52 | 106.52 | 1,036.36 | 1,665.60 | 0.4924 | 2.40 | 3.79 | 113,569,200.00 | 5.07 | 10.78 | 5.85 | 12.37 | 69.61 | 73.23 | 10.30 | 21.23 | 2.56 | 142.59 | 0.1569 | 36.33 | -3.14 | 10.73 | -60.89 | -3.47 | -18.66 | 12.20 |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 1.90bn | 518.12m | 4.09bn | 11.76k | 7.75 | 1.38 | 6.66 | 2.15 | 1,306.97 | 1,306.97 | 4,799.48 | 7,338.15 | 0.5758 | 1.31 | 3.81 | 74,690,570.00 | 15.68 | 13.55 | 17.35 | 15.35 | 68.75 | 60.79 | 27.24 | 22.34 | 3.08 | -- | 0.0156 | 40.47 | 6.51 | 11.05 | 50.61 | 38.39 | 8.62 | 51.82 |
| Axsome Therapeutics Inc | 322.12m | -207.42m | 4.12bn | 683.00 | -- | 103.83 | -- | 12.79 | -5.77 | -5.77 | 8.95 | 1.08 | 0.7566 | 2.31 | 3.29 | 632,733.50 | -48.72 | -59.62 | -73.77 | -80.32 | 91.49 | -- | -64.39 | -134.06 | 1.96 | -34.42 | 0.7784 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
| Dottikon ES Holding AG | 356.90m | 97.81m | 4.14bn | 793.00 | 41.82 | 4.45 | 35.05 | 11.61 | 7.64 | 7.64 | 27.88 | 71.79 | 0.303 | 0.6952 | 4.88 | 485,789.40 | 8.31 | 8.05 | 9.67 | 9.25 | 67.36 | 72.37 | 27.41 | 25.67 | 1.65 | -- | 0.1159 | -- | 18.07 | 17.13 | 30.95 | 26.06 | 23.40 | -- |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 7.73bn | 280.01m | 4.27bn | 28.14k | 16.09 | 1.15 | -- | 0.5524 | 1.66 | 1.66 | 45.84 | 23.20 | 0.9388 | 6.07 | 4.34 | 2,648,377.00 | 3.56 | 5.33 | 6.67 | 10.95 | 15.77 | 18.07 | 3.79 | 5.28 | 1.24 | -- | 0.3231 | 28.87 | -0.692 | 2.92 | -30.09 | -2.32 | -14.01 | 6.32 |
| Hikma Pharmaceuticals Plc | 2.35bn | 267.61m | 4.43bn | 9.31k | 16.67 | 2.57 | 10.70 | 1.88 | 1.20 | 1.20 | 10.53 | 7.76 | 0.6432 | 1.82 | 3.63 | 252,747.90 | 7.38 | 7.19 | 11.18 | 10.00 | 45.88 | 49.35 | 11.47 | 11.87 | 0.6456 | 7.58 | 0.3601 | 44.05 | 9.77 | 7.45 | 88.95 | -5.88 | 4.79 | 10.29 |
| Rhythm Pharmaceuticals Inc | 102.01m | -129.71m | 4.45bn | 283.00 | -- | 303.89 | -- | 43.64 | -2.78 | -2.78 | 2.22 | 2.57 | 0.4242 | 1.02 | 8.42 | 483,614.80 | -52.29 | -52.46 | -70.40 | -61.22 | 89.62 | -- | -123.28 | -354.18 | 3.13 | -- | 0.4018 | -- | 68.06 | -- | -43.26 | -- | -- | -- |
| ALK-Abello A/S | 661.05m | 108.51m | 4.55bn | 2.74k | 45.36 | 7.57 | 32.37 | 6.88 | 4.28 | 4.28 | 26.08 | 25.62 | 0.7625 | 1.26 | 6.44 | 2,073,375.00 | 12.52 | 6.01 | 15.29 | 7.60 | 64.45 | 61.95 | 16.42 | 8.44 | 0.9875 | 57.35 | 0.1235 | 0.00 | 14.78 | 11.08 | 67.70 | -- | 50.82 | -- |
| TG Therapeutics Inc | 288.00m | 29.18m | 4.64bn | 352.00 | 160.63 | 26.12 | 158.73 | 16.10 | 0.244 | 0.244 | 2.40 | 1.50 | 0.7503 | 0.4127 | 3.03 | 1,143,154.00 | 7.60 | -42.93 | 10.17 | -52.55 | 87.43 | -- | 10.13 | -142.45 | 3.04 | 2.25 | 0.5077 | -- | 40.80 | 364.59 | 84.52 | -- | -19.24 | -- |
| GlaxoSmithKline Pharmaceuticals Ltd | 324.82m | 80.36m | 4.66bn | 3.11k | 58.22 | 27.55 | 54.07 | 14.34 | 54.51 | 54.51 | 220.41 | 115.19 | 0.9783 | 2.76 | 14.57 | 12,043,720.00 | 24.20 | 15.30 | 43.81 | 25.66 | 62.90 | 56.70 | 24.74 | 16.77 | 1.54 | 845.38 | 0.0051 | 137.07 | 8.56 | 3.06 | 57.23 | 53.14 | -31.03 | 16.00 |
Data as of Jul 18 2025. Currency figures normalised to Hikma Pharmaceuticals PLC's reporting currency: UK Pound GBX
23.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| JPMorgan (Suisse) SAas of 01 Jun 2025 | 14.01m | 6.31% |
| Wellington Management Co. LLPas of 25 Feb 2025 | 11.15m | 5.03% |
| The Vanguard Group, Inc.as of 01 Jun 2025 | 5.76m | 2.60% |
| BlackRock Advisors (UK) Ltd.as of 25 Feb 2025 | 4.45m | 2.01% |
| Mawer Investment Management Ltd.as of 01 Jun 2025 | 3.92m | 1.77% |
| Royal London Asset Management Ltd.as of 01 Jun 2025 | 2.96m | 1.33% |
| Invesco Asset Management Ltd.as of 01 Jun 2025 | 2.94m | 1.33% |
| Polar Capital LLPas of 30 May 2025 | 2.66m | 1.20% |
| Jupiter Asset Management Ltd.as of 31 Mar 2025 | 2.30m | 1.03% |
| BlackRock Investment Management (UK) Ltd.as of 01 Jun 2025 | 2.21m | 0.99% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
